Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure

Heart

Volumn 97, Issue 18, 2011, Pages 1495-1500

  Fragasso, Gabriele ^a   Salerno, Anna ^a   Lattuada, Guido ^a   Cuko, Amarild ^a   Calori, Giliola ^a   Scollo, Antonella ^a   Ragogna, Francesca ^a   Arioli, Francesco ^a   Bassanelli, Giorgio ^a   Spoladore, Roberto ^a   Luzi, Livio ^a,b   Margonato, Alberto ^a   Perseghin, Gianluca ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; POLYUNSATURATED FATTY ACID; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY ACID OXIDATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; CALORIMETRY; CHRONIC DISEASE; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FATTY ACIDS; FEMALE; HEART FAILURE; HUMANS; MALE; OXIDATION-REDUCTION; STROKE VOLUME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 80052180144     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.226332     Document Type: Article

References (48)

1. Passeron J. Efficacy of trimetazidine in stable effort angina. Double-blind study against placebo. Presse Med 1986;15:1775-7.
2. Michaelides AP, Vyssoulis GP, Bonoris PE, et al. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res 1989;46:565-76. (Pubitemid 19232525)
3. Levy S. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol 1995;76:12B-16B.
4. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double blind, cross-over study. Cardiovasc Drug Ther 1990;4:853-60.
5. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279-388.
6. Chierchia S, Fragasso G. Metabolic management of ischaemic heart disease. Eur Heart J 1993;14(Suppl G):2-5. (Pubitemid 24040067)
7. Lavanchy N, Martin J, Rossi A. Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987;286:97-110. (Pubitemid 17043434)
8. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942-8.
9. Lagadic-Gossmann D, Le Prigent K, Feuvray D. Effects of trimetazidine on pHi in the rat isolated ventricular myocyte. Br J Pharmacol 1996;117:831-8.
10. Renaud JF. Internal pH, Na*, and Ca2* regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988;1:677-86.
11. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148-51. (Pubitemid 15240609)
12. Kay L, Finelli C, Aussedat J, et al. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: Effects on the energy state and mitochondrial function. Am J Cardiol 1995;76:45B-49B.
13. Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949-58. (Pubitemid 24279511)
14. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
15. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990;11:207-12. (Pubitemid 20119783)
16. Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: a double-blind, placebo-controlled, crossover study. Am J Cardiol 1998;82:898-901. (Pubitemid 28467367)
17. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J 2001;22:2164-70.
18. Fragasso G, Piatti Md PM, Monti L, et al. Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003;146:E1-8.
19. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814-21.
20. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161-5.
21. Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004;25:1765-8.
22. Thrainsdottir I, Von Bibra H, Malmberg K, et al. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44:101-8.
23. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with systolic dysfunction heart failure. J Am Coll Cardiol 2006;48:992-8. (Pubitemid 44292461)
24. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250-8.
25. Peabody FW, Meyer AL, Du Bois EF. The basal metabolism of patients with cardiac and renal disease. Arch Int Med 1916;17:980-1009.
26. Riley M, Elborn JS, McKane WR, et al. Resting energy expenditure in chronic cardiac failure. Clin Sci 1991;80:633-9.
27. Poehlman ET, Scheffers J, Gottlieb SS, et al. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 1994;121:860-2.
28. Beadle RM, Frenneaux M. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart 2010;96:824-30.
29. Perseghin G, Comola M, Scifo P, et al. Postabsorptive and insulinstimulated energy and protein metabolism in patients with myotonic dystrophy type 1. Am J Clin Nutr 2004;80:357-64. (Pubitemid 41080009)
30. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol (Lond) 1949;109:1-9.
31. Johnson MM, Chin R, Haponik EF. Nutrition, respiratory function, and disease. In: Shils ME, Olson JA, Shike M, et al, eds. 9th edition Modern Nutrition in Health and Disease, ed. Williams & Wilkins, Baltimore, 1999:1473-90.
32. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-6.
33. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278-86.
34. Lommi J, Kupari M, Yki-Järvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 1998;81:45-50. (Pubitemid 28046841)
35. Steinberg D, Nestel PJ, Buskirk ER, et al. Calorigenic effect of norepinephrine correlated with plasma free fatty acid turnover and oxidation. J Clin Invest 1964;43:167-176.
36. Landsberg L, Saville ME, Young JB. Sympathoadrenal system and regulation of thermogenesis. Am J Physiol 1984;247:E181-9.
37. Lommi J, Kupari M, Koskinen P, et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996;28:665-72. (Pubitemid 26288648)
38. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263-76. (Pubitemid 24262910)
39. How O-J, Aasum E, Kunnathus S, et al. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex-vivo mouse hearts. Am J Physiol 2005;83:183-90.
40. Katz AM. Is the failing heart energy depleted? Cardiol Clin 1998;16:633-44. (Pubitemid 28509447)
41. Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:e26-32.
42. MacInness A, Fairman DA, Binding P, et al. The antianginal trimetazidine does not exert its functional benefit via inhibition of mithocondrial longchain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:e33-7.
43. Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617-24.
44. Murray AJ, Anderson RE, Watson GC, et al. Uncoupling proteins in human heart. Lancet 2004;364:1786-8.
45. Doehner W, Gathercole D, Cicoira M, et al. Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. Int J Cardiol 2010;138:19-24.
46. Opie LH. The metabolic vicious circle in heart failure. Lancet 2004;364:1733-4.
47. Williams FM, Tanda K, Kus M, et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;22:828-33. (Pubitemid 23360404)
48. Tritto I, Wang P, Kuppusamy P, et al. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 2005;46:89-98. (Pubitemid 40917784)